EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

Hongwen Li, Jing Li, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Wenting Song, Jiwei Li, Zhaoming Li, Mingzhi Zhang iD

Cancer Medicine · 2023-05 · 12 (9) · 10804-10815

DOI: 10.1002/cam4.5818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 11.04.2023. Verfasst von Hongwen Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma (MM) is an aggressive plasma cell malignancy, causing a number of deaths worldwide every year. Chimeric antigen receptor (CAR) transduced T‐cell therapy has been a promising immunotherapy against hematological malignancies.

Methods

In this study, we developed a second‐generation CAR construct and generated CAR‐T cells targeting CD38 molecule. Then effects of CAR‐T cells against MM cell lines were evaluated.

Results

CD38‐CAR‐T cells showed higher cytotoxicity to MM cell lines and primary MM cells than that of control T cells in vitro. Over 50% MM1.s and RPMI8226 cells were killed by CAR‐T cells even at effector to target ratio of 1:100. CAR‐T cells also showed an enhanced cytotoxicity against primary MM cells. CAR‐T cells could be activated and produced a variety of cytokines in a target‐dependent manner. In vivo test indicated that CAR‐T cells also showed significant antitumor effect on xenograft mice models.

Conclusion

These results indicated a promising therapeutic strategy of CD38‐CAR‐T cells against MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaReceptors, Chimeric AntigenHumansAnimalsMiceT-LymphocytesReceptors, Antigen, T-CellImmunotherapyImmunotherapy, AdoptiveCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CD38chimeric antigen receptorimmunotherapymultiple myeloma

Substanzen

Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • State Key Laboratory of Esophageal Cancer Prevention and Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Academy of Medical Sciences of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Mingzhi Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, H., Li, J., Wu, J., Shi, Z., Gao, Y., Song, W., Li, J., Li, Z., & Zhang, M. (2023). A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma. Cancer Medicine, 12(9), 10804-10815. https://doi.org/10.1002/cam4.5818

Vancouver

Li H, Li J, Wu J, Shi Z, Gao Y, Song W, et al. A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma. Cancer Medicine. 2023;12(9):10804-10815. doi:10.1002/cam4.5818

BibTeX
@article{Li2023,
  author = {Li, Hongwen and Li, Jing and Wu, Jiazhuo and Shi, Zhuangzhuang and Gao, Yuyang and Song, Wenting and Li, Jiwei and Li, Zhaoming and Zhang, Mingzhi},
  title = {A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {9},
  pages = {10804--10815},
  doi = {10.1002/cam4.5818}
}
Kostenlos starten →